Generic competition forces J&J's Q3 pharma sales down by 14%
This article was originally published in Scrip
Johnson & Johnson has reported a 14% drop in pharmaceutical sales in the third quarter, to $5.3 billion. The company as a whole saw revenues decline by 5% to $15.1 billion, partly because of negative currency effects (which dragged down the result by 2.5%) but to a greater extent because of generic competition for its pharmaceutical products, particularly in the US.
You may also be interested in...
BioNTech extends Pfizer partnership to cover COVID-19 vaccine development and distribution while Fosun Pharma takes Chinese rights.
Dietmar Hopp, 80% shareholder of German mRNA company CureVac, has rejected the possibility that the company would sign an exclusive deal with the US for its investigational coronavirus vaccine.
Infographic: Scrip homes in on key figures for companies integrating major acquisitions or divesting significant parts of their business.